Optimal aspirin dose in acute coronary syndromes: An emerging consensus

James J. Dinicolantonio, Nicholas B. Norgard, Pascal Meier, Carl J. Lavie, James H. O'Keefe, Asfandyar K. Niazi, Saurav Chatterjee, Kathleen A. Packard, Fabrizio D'Ascenzo, Enrico Cerrato, Giuseppe Biondi-Zoccai, Sripal Bangalore, Flavio D. Fuchs, Victor L. Serebruany

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

Original languageEnglish
Pages (from-to)291-300
Number of pages10
JournalFuture Cardiology
Volume10
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Acute Coronary Syndrome
Aspirin
Clinical Trials
Secondary Prevention
Cardiovascular Diseases
Odds Ratio
Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine
  • Medicine(all)

Cite this

Dinicolantonio, J. J., Norgard, N. B., Meier, P., Lavie, C. J., O'Keefe, J. H., Niazi, A. K., ... Serebruany, V. L. (2014). Optimal aspirin dose in acute coronary syndromes: An emerging consensus. Future Cardiology, 10(2), 291-300. https://doi.org/10.2217/fca.14.7

Optimal aspirin dose in acute coronary syndromes : An emerging consensus. / Dinicolantonio, James J.; Norgard, Nicholas B.; Meier, Pascal; Lavie, Carl J.; O'Keefe, James H.; Niazi, Asfandyar K.; Chatterjee, Saurav; Packard, Kathleen A.; D'Ascenzo, Fabrizio; Cerrato, Enrico; Biondi-Zoccai, Giuseppe; Bangalore, Sripal; Fuchs, Flavio D.; Serebruany, Victor L.

In: Future Cardiology, Vol. 10, No. 2, 2014, p. 291-300.

Research output: Contribution to journalReview article

Dinicolantonio, JJ, Norgard, NB, Meier, P, Lavie, CJ, O'Keefe, JH, Niazi, AK, Chatterjee, S, Packard, KA, D'Ascenzo, F, Cerrato, E, Biondi-Zoccai, G, Bangalore, S, Fuchs, FD & Serebruany, VL 2014, 'Optimal aspirin dose in acute coronary syndromes: An emerging consensus', Future Cardiology, vol. 10, no. 2, pp. 291-300. https://doi.org/10.2217/fca.14.7
Dinicolantonio JJ, Norgard NB, Meier P, Lavie CJ, O'Keefe JH, Niazi AK et al. Optimal aspirin dose in acute coronary syndromes: An emerging consensus. Future Cardiology. 2014;10(2):291-300. https://doi.org/10.2217/fca.14.7
Dinicolantonio, James J. ; Norgard, Nicholas B. ; Meier, Pascal ; Lavie, Carl J. ; O'Keefe, James H. ; Niazi, Asfandyar K. ; Chatterjee, Saurav ; Packard, Kathleen A. ; D'Ascenzo, Fabrizio ; Cerrato, Enrico ; Biondi-Zoccai, Giuseppe ; Bangalore, Sripal ; Fuchs, Flavio D. ; Serebruany, Victor L. / Optimal aspirin dose in acute coronary syndromes : An emerging consensus. In: Future Cardiology. 2014 ; Vol. 10, No. 2. pp. 291-300.
@article{d87a1e99c5b44bccbc5b5e2e1634a734,
title = "Optimal aspirin dose in acute coronary syndromes: An emerging consensus",
abstract = "Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.",
author = "Dinicolantonio, {James J.} and Norgard, {Nicholas B.} and Pascal Meier and Lavie, {Carl J.} and O'Keefe, {James H.} and Niazi, {Asfandyar K.} and Saurav Chatterjee and Packard, {Kathleen A.} and Fabrizio D'Ascenzo and Enrico Cerrato and Giuseppe Biondi-Zoccai and Sripal Bangalore and Fuchs, {Flavio D.} and Serebruany, {Victor L.}",
year = "2014",
doi = "10.2217/fca.14.7",
language = "English",
volume = "10",
pages = "291--300",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Optimal aspirin dose in acute coronary syndromes

T2 - An emerging consensus

AU - Dinicolantonio, James J.

AU - Norgard, Nicholas B.

AU - Meier, Pascal

AU - Lavie, Carl J.

AU - O'Keefe, James H.

AU - Niazi, Asfandyar K.

AU - Chatterjee, Saurav

AU - Packard, Kathleen A.

AU - D'Ascenzo, Fabrizio

AU - Cerrato, Enrico

AU - Biondi-Zoccai, Giuseppe

AU - Bangalore, Sripal

AU - Fuchs, Flavio D.

AU - Serebruany, Victor L.

PY - 2014

Y1 - 2014

N2 - Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

AB - Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

UR - http://www.scopus.com/inward/record.url?scp=84899576762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899576762&partnerID=8YFLogxK

U2 - 10.2217/fca.14.7

DO - 10.2217/fca.14.7

M3 - Review article

C2 - 24762255

AN - SCOPUS:84899576762

VL - 10

SP - 291

EP - 300

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -